borax boiron 200k pilules
boiron - borax 200k 1 % - pillules - 200k - borax 200k 1 %
borax boiron 200k pilules single-dose cont.
boiron - borax 200k 1 % - pillules in single-dose container - 200k - borax 200k 1 %
borax boiron mk pilules single-dose cont.
boiron - borax mk 1 % - pillules in single-dose container - mk - borax mk 1 %
borax boiron xmk pilules single-dose cont.
boiron - borax xmk 1 % - pillules in single-dose container - xmk - borax xmk 1 %
fosamax- alendronate sodium tablet
merck sharp & dohme corp. - alendronate sodium (unii: 2uy4m2u3ra) (alendronic acid - unii:x1j18r4w8p) - alendronic acid 70 mg - fosamax® is indicated for the treatment of osteoporosis in postmenopausal women. in postmenopausal women, fosamax increases bone mass and reduces the incidence of fractures, including those of the hip and spine (vertebral compression fractures). [see clinical studies (14.1).] fosamax is indicated for the prevention of postmenopausal osteoporosis [see clinical studies (14.2)]. fosamax is indicated for treatment to increase bone mass in men with osteoporosis [see clinical studies (14.3)] . fosamax is indicated for the treatment of glucocorticoid-induced osteoporosis in men and women receiving glucocorticoids in a daily dosage equivalent to 7.5 mg or greater of prednisone and who have low bone mineral density [see clinical studies (14.4)]. fosamax is indicated for the treatment of paget's disease of bone in men and women. treatment is indicated in patients with paget's disease of bone who have alkaline phosphatase at least two times the upper limit of normal, or those who are symptomatic, or those at risk for f
fosamax plus d- alendronate sodium and cholecalciferol tablet
merck sharp & dohme corp. - alendronate sodium (unii: 2uy4m2u3ra) (alendronic acid - unii:x1j18r4w8p), cholecalciferol (unii: 1c6v77qf41) (cholecalciferol - unii:1c6v77qf41) - alendronic acid 70 mg - fosamax® plus d is indicated for the treatment of osteoporosis in postmenopausal women. in postmenopausal women, fosamax plus d increases bone mass and reduces the incidence of fractures, including those of the hip and spine (vertebral compression fractures). [see clinical studies (14.1).] fosamax plus d is indicated for treatment to increase bone mass in men with osteoporosis [see clinical studies (14.2)]. fosamax plus d alone should not be used to treat vitamin d deficiency. the optimal duration of use has not been determined. the safety and effectiveness of fosamax plus d for the treatment of osteoporosis are based on clinical data of four years duration. all patients on bisphosphonate therapy should have the need for continued therapy re-evaluated on a periodic basis. patients at low-risk for fracture should be considered for drug discontinuation after 3 to 5 years of use. patients who discontinue therapy should have their risk for fracture re-evaluated periodically. fosamax plus d is contraindicated in
fosamax plus d- alendronate sodium and cholecalciferol tablet
physicians total care, inc. - alendronate sodium (unii: 2uy4m2u3ra) (alendronic acid - unii:x1j18r4w8p), cholecalciferol (unii: 1c6v77qf41) (cholecalciferol - unii:1c6v77qf41) - alendronic acid 70 mg - fosamax® plus d is indicated for: for the treatment of osteoporosis, fosamax plus d increases bone mass and reduces the incidence of fractures, including those of the hip and spine (vertebral compression fractures). fosamax plus d alone should not be used to treat vitamin d deficiency. the safety and effectiveness of fosamax plus d for the treatment of osteoporosis are based on clinical data of four years duration. the optimal duration of use has not been determined. all patients on bisphosphonate therapy should have the need for continued therapy re-evaluated on a periodic basis. - abnormalities of the esophagus which delay esophageal emptying such as stricture or achalasia [see warnings and precautions (5.1)] - inability to stand or sit upright for at least 30 minutes [see dosage and administration (2.3), warnings and precautions (5.1)] - hypocalcemia [see warnings and precautions (5.2)] - hypersensitivity to any component of this product. hypersensitivity reactions including urticaria and angioedema have
fosamax 10mg tablets
organon pharma (uk) ltd - alendronate sodium - oral tablet - 10mg
fosamax once weekly 70mg tablets
organon pharma (uk) ltd - alendronate sodium - oral tablet - 70mg
fosamax once weekly 70mg tablets
de pharmaceuticals - alendronate sodium - oral tablet - 70mg